The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone.
Lurcott
G
G
School of Dentistry, University of Michigan, Ann Arbor, USA.
D000701:Analgesics, Opioid / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000889:Anti-Arrhythmia Agents / Q000378:metabolism; D001667:Binding, Competitive; D003061:Codeine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D019389:Cytochrome P-450 CYP2D6 / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004791:Enzyme Inhibitors / Q000378:metabolism; D005473:Fluoxetine / Q000378:metabolism; D006801:Humans; D006853:Hydrocodone / Q000037:antagonists & inhibitors / Q000378:metabolism; D010098:Oxycodone / Q000037:antagonists & inhibitors / Q000378:metabolism; D017374:Paroxetine / Q000378:metabolism; D011802:Quinidine / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000378:metabolism
D000701:Analgesics, Opioid; D000889:Anti-Arrhythmia Agents; D003061:Codeine; D019389:Cytochrome P-450 CYP2D6; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004791:Enzyme Inhibitors; D005473:Fluoxetine; D006853:Hydrocodone; D010098:Oxycodone; D017374:Paroxetine; D011802:Quinidine; D017367:Selective Serotonin Reuptake Inhibitors